Markus Kosel

Dr. Markus Kosel

Adult Psychiatry, Geneva University Hospitals and Faculty of Medicine, Geneva, Genève, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2007 in Neuropsychopharmacology
Verified
Journal Article
Closed access
TSThomas E Schlaepfer
Thomas E Schlaepfer
MCMichael X Cohen
Michael X Cohen
CFCaroline Frick
Caroline Frick
MKMarkus Kosel
Markus Kosel
DBDaniela Brodesser
Daniela Brodesser
VSVolker Sturm
Volker Sturm

1 April 2004 in Psychiatry Research
Verified
Journal Article
Closed access
UMUrs P. Mosimann
Urs P. Mosimann
WSWolfgang Schmitt
Wolfgang Schmitt
BGBenjamin D. Greenberg
Benjamin D. Greenberg
MKMarkus Kosel
Markus Kosel
RMRené Müri
René Müri
TSThomas E. Schlaepfer
Thomas E. Schlaepfer

1 January 2009 in Current Opinion in Psychiatry
Verified
Journal Article
Closed access
CDCristian Damsa
Cristian Damsa
MKMarkus Kosel
Markus Kosel
JMJoanna Moussally
Joanna Moussally
This study reviews the most recent literature about brain imaging research in anxiety disorders. There is a growing body of evidence that neuroimaging of anxiety disorders contributes to a better understanding of the neurobiology of these disorders, by identifying cerebral modifications occurring previously or subsequent to symptoms of anxiety. A systematic search of the literature (January 1978-July 2008) was performed in MEDLINE using the keywords brain imaging, anxiety disorders, posttraumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, specific phobia, social anxiety disorder, panic disorders and agoraphobia. References cited in all trials were searched iteratively to identify missing studies. Our review focused only on the last year's findings. There is a consensus on the crucial role of the amygdala, anterior cingulate cortex and insula in the pathophysiology of anxiety disorders. Brain imaging research in anxiety disorders has become increasingly important, especially in the last decade, because of the opportunity to validate neurobiological hypotheses for anxiety disorders. Thus, neuroimaging data raise the question of the neurobiological cause of anxiety disorders, opening up new reflections not only on pharmacological treatments but also on the nosology of the anxiety disorders.

18 July 2003 in Neuropsychopharmacology
Verified
Journal Article
Closed access
MKMarkus Kosel
Markus Kosel
CFCaroline Frick
Caroline Frick
SLSarah Hollingsworth Lisanby
Sarah Hollingsworth Lisanby
HFHans-Ulrich Fisch
Hans-Ulrich Fisch
TSThomas E Schlaepfer
Thomas E Schlaepfer

1 April 2001 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
CEChin B. Eap
Chin B. Eap
FBFranck Broly
Franck Broly
AMAnnie Mino
Annie Mino
RHRobert Hammig
Robert Hammig
JDJean J. Déglon
Jean J. Déglon
PBPierre Baumann
Pierre Baumann
A genetic polymorphism of cytochrome P450 2D6 has been described with the existence of poor (zero functional genes), extensive (one or two functional genes), and ultrarapid metabolizers (three or more functional genes). The authors measured the steady-state trough (R)- (i.e., the active enantiomer), (S)-, and (R,S)-methadone plasma levels in opiate-dependent patients receiving methadone maintenance treatment (MMT) and genotyped them for cytochrome P4502D6. The patients' medical records were reviewed to assess the outcome of the MMT with regard to the absence of illicit opiate consumption and to the absence of withdrawal complaints in ultrarapid and poor metabolizers. Of 256 patients included, 18 were found to be poor metabolizers, 228 to be extensive metabolizers, and 10 to be ultrarapid metabolizers. Significant differences were found between genotypes for (R)- (p = 0.024), (S)- (p = 0.033), and (R,S)-methadone (p = 0.026) concentrations to dose-to-weight ratios. For (R)-methadone, a significant difference was found between ultrarapid metabolizers and poor metabolizers (p = 0.009), with the median value in the former group being only 54% of the median value in the latter group. These results confirm the involvement of cytochrome P450 2D6 in methadone metabolism. Although the difference was nonsignificant (p = 0.103), 13 (72%) of the 18 poor metabolizers and only 4 (40%) of the 10 ultrarapid metabolizers were considered successful in their treatment. More studies are needed to examine the influence of the ultrarapid metabolizer status on the outcome of the MMT.

1 November 2007 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
MKMarkus Kosel
Markus Kosel
VSVolker Sturm
Volker Sturm
CFCaroline Frick
Caroline Frick
DLDoris Lenartz
Doris Lenartz
GZGabriele Zeidler
Gabriele Zeidler
TSThomas E. Schlaepfer
Thomas E. Schlaepfer